Shasqi
Shasqi is pioneering ADC innovation through its CAPAC® platform, which uses click chemistry to activate protodrugs at tumor sites. This modular system separates targeting from payload delivery, enabling high-dose chemotherapy with reduced toxicity. Based in San Francisco, Shasqi’s approach enhances ADC precision and expands therapeutic windows. Its clinical programs demonstrate significantly increased drug delivery with manageable side effects. Shasqi’s platform is adaptable to ADCs and radiotherapeutics, offering a transformative solution for targeted cancer treatment.
